Bg pattern

GALAFOLD 123 mg HARD CAPSULES

Prescription review online

Prescription review online

A doctor will review your case and decide whether a prescription is medically appropriate.

Talk to a doctor about this medicine

Talk to a doctor about this medicine

Discuss your symptoms and possible next steps in a quick online consultation.

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use GALAFOLD 123 mg HARD CAPSULES

Translated with AI

This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.

Show original

Introduction

Package Leaflet: Information for the Patient

Galafold 123 mg Hard Capsules

Migalastat

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

  • Keep this leaflet, you may need to read it again.
  • If you have any further questions, ask your doctor, pharmacist, or nurse.
  • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
  • If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

Contents of the Package Leaflet

  1. What is Galafold and what is it used for
  2. What you need to know before you take Galafold
  3. How to take Galafold
  4. Possible side effects
  5. Storage of Galafold
  6. Contents of the pack and other information

1. What is Galafold and what is it used for

Galafold contains the active substance migalastat.

This medicine is used for the long-term treatment of Fabry disease in adults and adolescents aged 12 years and older with certain genetic mutations (changes in genetic material).

Fabry disease is caused by a deficiency of an enzyme called alpha-galactosidase A (α-Gal A). Depending on the type of mutation (change in genetic material) of the gene that produces α-Gal A, the enzyme may not work properly or be completely absent. This enzyme deficiency leads to abnormal accumulations of a fatty substance called globotriaosylceramide (GL-3) in the kidneys, heart, and other organs, causing the symptoms of Fabry disease.

This medicine works by stabilizing the enzyme that the body produces naturally, so that it can work better to reduce the amount of GL-3 accumulated in cells and tissues.

Doctor consultation

Not sure if this medicine is right for you?

Discuss your symptoms and treatment with a doctor online.

2. What you need to know before you take Galafold

Do not take Galafold:

  • if you are allergic to migalastat or any of the other ingredients of this medicine (listed in section 6).

Warnings and Precautions

The 123 mg migalastat capsules are not indicated for children (≥12 years) weighing less than 45 kg.

Tell your doctor before taking Galafold if you are using enzyme replacement therapy.

Do not take Galafold if you are also using enzyme replacement therapy.

While taking Galafold, your doctor should assess your condition and whether your medicine is working every 6 months. If your condition worsens, your doctor should perform additional tests or stop treatment with Galafold.

Consult your doctor before taking Galafold if your kidney function is severely impaired, as Galafold is not recommended for use in patients with severe renal impairment (with an eGFR below 30 ml/min/1.73 m2).

Children

Children <12 years

This medicine has not been studied in children under 12 years of age. Therefore, the safety and efficacy in this age group have not been established.

Other medicines and Galafold

Tell your doctor, pharmacist, or nurse if you are taking, have recently taken, or might take any other medicines. This includes medicines obtained without a prescription, such as supplements or herbal medicines.

Tell your doctor especially if you take medicines or supplements that contain caffeine, as these medicines may affect the activity of Galafold if taken during the fasting period.

Be aware of the medicines you take. Keep a list of them and show it to your doctor and pharmacist each time you get a new medicine.

Pregnancy, breastfeeding, and fertility

Pregnancy

There are very limited data on the use of this medicine in pregnant women. Galafold is not recommended during pregnancy. If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor for advice before taking this medicine.

Women who can become pregnant must use an effective method of contraception while using Galafold.

Breastfeeding

Do not take this medicine if you are breastfeeding until you have talked to your doctor, pharmacist, or nurse. It is not known if this medicine is excreted in breast milk. Your doctor will decide whether you should stop breastfeeding or stop treatment with Galafold, considering the benefit of breastfeeding for the baby and the benefit of Galafold for the mother.

Male fertility

It is not known if this medicine affects male fertility. The effects of Galafold on fertility in humans have not been studied.

Female fertility

It is not known if this medicine affects female fertility.

If you are planning to become pregnant, consult your doctor, pharmacist, or nurse.

Driving and using machines

This medicine is not expected to affect your ability to drive or use machines.

3. How to take Galafold

Follow exactly the administration instructions of this medicine given by your doctor or pharmacist. If you are unsure, ask your doctor, pharmacist, or nurse.

The recommended dose is one capsule every two days at the same time of day. Do not take Galafold on two consecutive days.

Do not eat any food or caffeine for at least 2 hours before and 2 hours after taking the medicine. This 4-hour fasting period around the time of taking the medicine is necessary to allow the medicine to be fully absorbed.

During the 4-hour fasting period, you can consume water (natural, flavored, sugared), fruit juices without pulp, and non-caffeinated carbonated drinks.

Swallow the capsules whole. Do not split, crush, or chew the capsules.

Figure A

Hands holding an auto-injector device with a transparent window showing the plunger and circular buttons

Step 1: Remove the adhesive strip that keeps the flap closed.

Lift the flap to open the Galafold carton (see Figure A).

Figure B: Open carton

Hands holding an informational booklet with illustrations of a medical device and usage steps indicated

Step 2: Press the purple tab with your thumb on the leftside of the carton without releasing it (see Figure B) and proceed to step 3.

Figure C

Hand holding a blister pack of tablets with black and white circles indicating dosage and administration sequence

Step 3: Now GRASP the tab on the rightside, where it says “PULL HERE”, and pull out the folded blister pack (see Figure C).

Figure D: Front of the blister pack

Strip of tablets with 12 oval capsules, some darkened to indicate dosage, held by two fingers

Step 4: Unfold the blister pack (see Figure D).

How to take the Galafold capsules:

One Galafold blister pack = 14 hard capsules = 28 days of treatment with Galafold and 14 white circles.

The white circles are to remind you to take Galafold every twodays.

The arrow indicates to the patient that they should start the next 2 weeks of treatment.

Figure E: Front of the blister pack

Blister pack with oval tablets marked with days 1 to 28 and an arrow indicating the start

Figure F: Front of the blister pack

Hand holding an auto-injector with date markers for days 1, 2, 4, 6, and 8 indicating injection progress

Step 5: On the first day you start with this medicine, mark the date on the new blister pack (see Figure F).

Figure G: Back of the blister pack

Hands opening a blister pack of tablets with a rectangular shape perforated with circles

Step 6: TURN OVER the blister pack to see the back.

LOCATE the capsule you are going to remove.

FOLD the blister pack as indicated here (see Figure G).

Note: When folding the blister pack, the perforated oval stands out.

Hand holding a syringe with a needle inserted into the skin showing the angle of injection and a shaded subcutaneous area Figure H: Back of the blister pack

Step 7: REMOVE the perforated oval (see Figure H).

Note: When removing the oval, the white backing sheet may still remain. This is correct.

Figure I: Front of the blister pack

Dotted oval outlining a white space with evenly distributed black dots aroundFinger pressing a pill calendar with days 2, 3, 4, 5, 6, and 7 marked and the start date indicated

Step 8: TURN OVER the blister pack to see the front.

PUSH the capsule to remove it (see Figure I).

Figure J: Front of the blister pack

Hand pressing a blister pack with tablets marked with days 1, 3, 5, and 6 along with circles for days 2, 4, and 6

Step 9: The next day, move to the white circle in the top row marked as Day 2.

Press the white circle to perforate it (see Figure J).

Note: Perforating this white circle will help you remember which days you should not take the medicine.

Take 1 Galafold capsule every twodays.

Close and store the box after each use.

After Day 2, move to Day 3 of the blister pack.

Alternate the days you take the capsule and perforate the white circles, until day 28, including this last day.

Figure K: Front of the unfolded blister pack

Monthly calendar with circles to mark days from day 1 to 27 and a box to indicate the date

If you take more Galafold than you should

If you take more capsules than you should, stop taking the medicine and consult your doctor. You may experience headache and dizziness.

If you forget to take Galafold

If you forget to take the capsule at the usual time and remember later, you can take the capsule only if it is within the next 12 hours after the usual time you take the dose. If more than 12 hours have passed, you should take Galafold the next day at the usual time, according to the every-other-day dosing schedule. Do not take a double dose to make up for forgotten doses.

If you stop taking Galafold

Do not stop treatment without talking to your doctor first.

If you have any further questions on the use of this medicine, ask your doctor, pharmacist, or nurse.

Medicine questions

Started taking the medicine and have questions?

Discuss your symptoms and treatment with a doctor online.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Very common: may affect more than 1 in 10 people

  • Headache

Common: may affect up to 1 in 10 people

  • Palpitations (feeling of strong heartbeats)
  • Abnormal feeling of movement (vertigo)
  • Diarrhea
  • Nausea
  • Stomach pain
  • Constipation
  • Dry mouth
  • Sudden need to defecate (to go to the bathroom)
  • Indigestion (dyspepsia)
  • Fatigue
  • High levels of creatine phosphokinase in the blood
  • Weight gain
  • Muscle spasms
  • Muscle pain (myalgia)
  • Painful stiff neck (torticollis)
  • Numbness or tingling in the limbs (paresthesia)
  • Dizziness
  • Reduced sense of touch (hypoesthesia)
  • Depression
  • Protein in the urine (proteinuria)
  • Shortness of breath (dyspnea)
  • Nosebleeds (epistaxis)
  • Rash
  • Persistent itching (pruritus)
  • Pain

Reporting of side effects

If you experience any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly through the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of Galafold

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and blister pack after EXP. The expiry date is the last day of the month shown.

This medicine does not require any special storage conditions. Store in the original package to protect from moisture.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.

6. Package Contents and Additional Information

Composition of Galafold

  • The active ingredient is migalastat. Each capsule contains migalastat hydrochloride equivalent to 123 mg of migalastat
  • The other ingredients are:

Capsule content: pregelatinized starch (corn) and magnesium stearate

Capsule shell: gelatin, titanium dioxide (E171), and indigo carmine (E132)

Printing ink: shellac, iron oxide black, and potassium hydroxide

Appearance of Galafold and Package Contents

Hard blue and white opaque capsules marked with «A1001» in black ink, hard capsule size 2 (6.4 x 18.0 mm) containing a white to light brown powder.

Galafold is available in a blister pack of 14 capsules.

Marketing Authorization Holder

Amicus Therapeutics Europe Limited

Block 1, Blanchardstown Corporate Park

Ballycoolin Road

Blanchardstown, Dublin

D15 AKK1

Ireland

Tel: +353 (0) 1 588 0836

Fax: +353 (0) 1 588 6851

e-mail: [email protected]

Manufacturer

Almac Pharma Services (Ireland) Limited

Finnabair Industrial Estate

Dundalk, Co. Louth

A91 P9KD

Ireland

You can request more information about this medicinal product by contacting the local representative of the marketing authorization holder (if you cannot contact your Amicus representative by phone, please contact us through the email address listed below):

Belgium

Amicus Therapeutics Europe Limited

Tel: (+32) 0800 89172

e-mail: [email protected]

Lithuania

Amicus Therapeutics Europe Limited

Tel.: (+370) 8800 33167

e-mail: [email protected]

Bulgaria

Amicus Therapeutics Europe Limited

Tel: (+359) 00800 111 3214

e-mail: [email protected]

Luxembourg

Amicus Therapeutics Europe Limited

Tel: (+352) 800 27003

e-mail: [email protected]

Czech Republic

Amicus Therapeutics Europe Limited

Tel.: (+420) 800 142 207

e-mail: [email protected]

Hungary

Amicus Therapeutics Europe Limited

Tel.: (+36) 06 800 21202

e-mail: [email protected]

Denmark

Amicus Therapeutics Europe Limited

Tel: (+45) 80 253 262

e-mail: [email protected]

Malta

Amicus Therapeutics Europe Limited

Tel: (+356) 800 62674

e-mail: [email protected]

Germany

Amicus Therapeutics GmbH

Tel.: (+49) 0800 000 2038

e-mail: [email protected]

Netherlands

Amicus Therapeutics BV

Tel: (+31) 0800 022 8399

e-mail: [email protected]

Estonia

Amicus Therapeutics Europe Limited

Tel: (+372) 800 0111 911

e-mail: [email protected]

Norway

Amicus Therapeutics Europe Limited

Tel: (+47) 800 13837

e-mail: [email protected]

Greece

Amicus Therapeutics Europe Limited

Tel.: (+30) 00800 126 169

e-mail: [email protected]

Austria

Amicus Therapeutics Europe Limited

Tel: (+43) 0800 909 639

e-mail: [email protected]

Spain

Amicus Therapeutics S.L.U.

Tel: (+34) 900 941 616

e-mail: [email protected]

Poland

Amicus Therapeutics Europe Limited

Tel.: (+48) 0080 012 15475

e-mail: [email protected]

France

Amicus Therapeutics SAS

Tel: (+33) 0 800 906 788

e-mail: [email protected]

Portugal

Amicus Therapeutics Europe Limited

Tel: (+351) 800 812 531

e-mail: [email protected]

Croatia

Amicus Therapeutics Europe Limited

Tel: (+385) 0800 222 452

e-mail: [email protected]

Romania

Amicus Therapeutics Europe Limited

Tel.: (+40) 0808 034 288

e-mail: [email protected]

Ireland

Amicus Therapeutics Europe Limited

Tel: (+353) 1800 936 230

e-mail: [email protected]

Slovenia

Amicus Therapeutics Europe Limited

Tel.: (+386) 0800 81794

e-mail: [email protected]

Iceland

Amicus Therapeutics Europe Limited

Tel: (+354) 800 7634

e-mail: [email protected]

Slovakia

Amicus Therapeutics Europe Limited

Tel.: (+421) 0800 002 437

e-mail: [email protected]

Italy

Amicus Therapeutics S.r.l.

Tel: (+39) 800 795 572

e-mail: [email protected]

Finland

Amicus Therapeutics Europe Limited

Tel: (+358) 0800 917 780

e-mail: [email protected]

Cyprus

Amicus Therapeutics Europe Limited

Tel.: (+357) 800 97595

e-mail: [email protected]

Sweden

Amicus Therapeutics Europe Limited

Tel: (+46) 020 795 493

e-mail: [email protected]

Latvia

Amicus Therapeutics Europe Limited

Tel.: (+371) 800 05391

e-mail: [email protected]

United Kingdom (Northern Ireland)

Amicus Therapeutics, UK Limited

Tel: (+44) 08 0823 46864

e-mail: [email protected]

Date of Last Revision of this Leaflet

Detailed information on this medicinal product is available on the European Medicines Agency website: http://www.ema.europa.eu. There are also links to other websites on rare diseases and orphan medicines.

Online doctors for GALAFOLD 123 mg HARD CAPSULES

Discuss questions about GALAFOLD 123 mg HARD CAPSULES, including use, safety considerations and prescription review, subject to medical assessment and local regulations.

5.0 (69)
Doctor

Tarek Agami

General medicine 11 years exp.

Dr. Tarek Agami is a general practitioner registered in both Portugal and Israel, with broad experience in family and preventive medicine. He offers online consultations for adults and children, providing personalised support for primary care needs, chronic disease management, and everyday health concerns.

Dr. Agami received clinical training and worked in leading medical institutions in Israel (Kaplan Medical Center, Barzilai Medical Center, Wolfson Medical Center) and Portugal (European Healthcare City, Viscura Internacional, Hospital Dr. José Maria Grande, Hospital Vila Franca de Xira). His approach combines international medical standards with individualised attention to each patient.

Main areas of consultation:

  • Diagnosis and treatment of acute and chronic conditions (high blood pressure, diabetes, respiratory infections, cardiovascular symptoms)
  • Evaluation of symptoms and guidance on further diagnostic testing
  • Preventive check-ups and regular health monitoring
  • Medical support during travel or after relocation
  • Treatment adjustments and lifestyle recommendations based on your personal history
Dr. Agami provides medical support for patients using GLP-1 medications (such as Ozempic or Mounjaro) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Portugal and Israel.

Dr. Agami is committed to evidence-based, patient-centred care, ensuring that each person receives trusted medical support tailored to their health goals.

Camera Book a video appointment
€69
5.0 (63)
Doctor

Nuno Tavares Lopes

Family medicine 18 years exp.

Dr. Nuno Tavares Lopes is a licensed physician in Portugal with 17 years of experience in emergency medicine, family and general practice, and public health. He is the Director of Medical and Public Health Services at an international healthcare network and serves as an external consultant for the WHO and ECDC.

  • Emergency care: infections, fever, chest/abdominal pain, minor injuries, paediatric emergencies
  • Family medicine: hypertension, diabetes, cholesterol, chronic disease management
  • Travel medicine: pre-travel advice, vaccinations, fit-to-fly certificates, travel-related illnesses
  • Sexual and reproductive health: PrEP, STD prevention, counselling, treatment
  • Weight management and wellness: personalised weight loss programmes, lifestyle guidance
  • Skin and ENT issues: acne, eczema, allergies, rashes, sore throat, sinusitis
  • Pain management: acute and chronic pain, post-surgical care
  • Public health: prevention, health screenings, long-term monitoring
  • Sick leave (Baixa médica) connected to Segurança Social in Portugal
  • IMT medical certificates for driving licence exchange
Dr. Nuno Tavares Lopes provides medical support for patients using GLP-1 medications (Mounjaro, Wegovy, Ozempic, Rybelsus) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Europe.

Dr. Lopes also provides interpretation of medical tests, follow-up care for complex patients, and multilingual support. Whether for urgent concerns or long-term care, he helps patients act with clarity and confidence.

Camera Book a video appointment
€59
0.0 (0)
Doctor

Hocine Lokchiri

General medicine 21 years exp.

Dr. Hocine Lokchiri is a French consultant with over 20 years of experience in General and Emergency Medicine. He works with adults and children, helping patients with urgent symptoms, infections, sudden health changes and everyday medical concerns that require timely evaluation. His background includes clinical practice in France, Switzerland and the United Arab Emirates, which allows him to navigate different healthcare systems and manage a wide range of conditions with confidence. Patients value his calm, structured approach, clear explanations and evidence-based decision-making.

Online consultations with Dr. Lokchiri are suitable for many situations when someone needs quick medical guidance, reassurance or a clear next step. Common reasons for booking include:

  • fever, chills, fatigue and viral symptoms
  • cough, sore throat, nasal congestion, breathing discomfort
  • bronchitis and mild asthma flare-ups
  • nausea, diarrhoea, abdominal pain, digestive infections
  • rashes, allergic reactions, redness, insect bites
  • muscle or joint pain, mild injuries, sprains
  • headache, dizziness, migraine symptoms
  • stress-related symptoms, sleep disturbances
  • questions about test results and treatment plans
  • management of chronic conditions in stable phases
Many patients reach out when symptoms appear suddenly and cause concern, when a child becomes unwell unexpectedly, when a rash changes or spreads, or when it’s unclear whether an in-person examination is necessary. His emergency medicine background is particularly valuable online, helping patients understand risk levels, identify warning signs and choose safe next steps.

Some situations are not suitable for online care. If a patient has loss of consciousness, severe chest pain, uncontrolled bleeding, seizures, major trauma or symptoms suggesting a stroke or heart attack, he will advise seeking immediate local emergency services. This improves safety and ensures patients receive the right level of care.

Dr. Lokchiri’s professional training includes:

  • Advanced Trauma Life Support (ATLS)
  • Basic and Advanced Cardiac Life Support (BLS/ACLS)
  • Pediatric Advanced Life Support (PALS)
  • Prehospital Trauma Life Support (PHTLS)
  • eFAST and critical care transthoracic echocardiography
  • aviation medicine
He is an active member of several professional organisations, including the French Society of Emergency Medicine (SFMU), the French Association for Emergency Physicians (AMUF) and the Swiss Society of Emergency and Rescue Medicine (SGNOR). In consultations, he works with clarity and precision, helping patients understand their symptoms, possible risks and the safest treatment options.
Camera Book a video appointment
€58
5.0 (3)
Doctor

Tomasz Grzelewski

Dermatology 21 years exp.

Dr Tomasz Grzelewski is an MD, PhD specialist in allergy, paediatrics, general practice and sports medicine, with a clinical focus on dermatology, endocrinology, allergology and sports-related health. He has more than 20 years of clinical experience and completed his medical training at the Medical University of Łódź, where he defended his PhD thesis with distinction. His doctoral research was recognised by the Polish Society of Allergology for its innovative contribution to the field. Throughout his career, he has gained extensive expertise in diagnosing and managing a wide range of allergic and paediatric conditions, including modern allergen desensitisation techniques.

For five years, Dr Grzelewski served as the Head of two paediatric departments in Poland, managing complex clinical cases and leading multidisciplinary teams. He also worked in medical centres in the United Kingdom, gaining experience across both primary care and specialist environments. With over a decade of telemedicine experience, he has provided online consultations across Europe and is valued for his clear, structured and evidence-based medical guidance.

Dr Grzelewski is actively involved in clinical programmes focused on modern anti-allergic therapies. As a Principal Investigator, he leads research projects on sublingual and oral allergen desensitisation, supporting evidence-based progress in allergy treatment for both children and adults.

In addition to his background in allergology and paediatrics, he completed dermatology studies through the Cambridge Education Group (Royal College of Physicians of Ireland) and a Clinical Endocrinology course at Harvard Medical School. This advanced training enhances his ability to manage skin manifestations of allergies, atopic conditions, urticaria, endocrine-related symptoms and complex immunological reactions.

Patients commonly seek his care for:

  • seasonal and perennial allergies
  • allergic rhinitis and chronic nasal symptoms
  • asthma and breathing difficulties
  • food and medication allergies
  • urticaria, atopic dermatitis and skin reactions
  • recurrent infections in children
  • sports-related health questions
  • general family medicine concerns
Dr Tomasz Grzelewski is known for his clear communication style, structured medical approach and ability to explain treatment options in a concise and accessible way. His multidisciplinary background across allergy, paediatrics, dermatology and endocrinology allows him to provide safe, up-to-date and comprehensive care for patients of all ages.
Camera Book a video appointment
€80

Frequently Asked Questions

Is a prescription required for GALAFOLD 123 mg HARD CAPSULES?
GALAFOLD 123 mg HARD CAPSULES requires a prescription in Spain. You can check with a doctor online whether this medicine may be appropriate for your situation.
What is the active substance in GALAFOLD 123 mg HARD CAPSULES?
The active ingredient in GALAFOLD 123 mg HARD CAPSULES is migalastat. This information helps identify medicines with the same composition but different brand names.
Who manufactures GALAFOLD 123 mg HARD CAPSULES?
GALAFOLD 123 mg HARD CAPSULES is manufactured by Amicus Therapeutics Europe Limited. Pharmacy brands and packaging may differ depending on the distributor.
Which doctors can assess the use of GALAFOLD 123 mg HARD CAPSULES online?
Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether GALAFOLD 123 mg HARD CAPSULES is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.
What are the alternatives to GALAFOLD 123 mg HARD CAPSULES?
Other medicines with the same active substance (migalastat) include AMMONAPS 500 mg TABLETS, AMMONAPS 940 mg/g GRANULES, CERDELGA 84 mg HARD CAPSULES. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.
bg-pattern-dark

Stay informed about Oladoctor

News about new services, product updates and useful information for patients.

Follow us on social media